Ascendis Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.6M
Doctors Paid
2,551
Transactions
11,782
2024 Total
$4.2M
Payment Breakdown by Category
Research$11.1M (82.2%)
Consulting$417,251 (3.1%)
Travel$293,413 (2.2%)
Food & Beverage$239,513 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.1M | 3,260 | 82.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 577 | 10.8% |
| Consulting Fee | $417,251 | 145 | 3.1% |
| Travel and Lodging | $293,413 | 1,100 | 2.2% |
| Food and Beverage | $239,513 | 6,664 | 1.8% |
| Education | $367.36 | 36 | 0.0% |
Payments by Type
Research
$11.1M
3,260 transactions
General
$2.4M
8,522 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| foresiGHt | $2.5M | 0 | 274 |
| New InsiGHts | $1.7M | 0 | 703 |
| enliGHten | $1.6M | 0 | 510 |
| foresiGHt extension | $1.0M | 0 | 136 |
| PaTH Forward | $863,837 | 0 | 179 |
| ApproaCH | $742,970 | 0 | 54 |
| PaTHway TRIAL | $694,652 | 1 | 107 |
| EAP of Palopegteriparatide in Patients With Hypoparathyroidism | $566,781 | 0 | 1,064 |
| SkybriGHt | $552,858 | 1 | 83 |
| SkyPASS | $540,885 | 1 | 81 |
| PaTHway | $204,267 | 0 | 54 |
| Emerald | $117,310 | 0 | 7 |
| IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 / Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies | $52,838 | 0 | 7 |
| BelieveIT-201 | $34,710 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 103
No doctor payment records found.
About Ascendis Pharma, Inc.
Ascendis Pharma, Inc. has made $13.6M in payments to 2,551 healthcare providers, recorded across 11,782 transactions in the CMS Open Payments database. In 2024, the company paid $4.2M. The top product by payment volume is SKYTROFA ($5.8M).
Payments were distributed across 82 medical specialties. The top specialty by payment amount is Pediatric Endocrinology ($996,259 to 291 doctors).
Payment categories include: Food & Beverage ($239,513), Consulting ($417,251), Research ($11.1M), Travel & Lodging ($293,413).
Ascendis Pharma, Inc. is associated with 3 products in the CMS Open Payments database.